Drugs / GS-9256
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01225380 | Oct 2010 → Jan 2013 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01072695 | Feb → Oct 2010 | hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-9256 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01225380 ↗ |
| Action | Inhibit | “GS-9256 (an HCV NS3 protease inhibitor)” NCT01072695 ↗ |
| Modality | Small molecule | — CHEMBL1956820 ↗ |
| Route | Oral | “GS-9256 plus GS-9190, two oral anti HCV drugs” NCT01072695 ↗ |